EUVIMEDEUVIMED entdecken
Crossref

Genetic prognostic markers in LymphGen-unclassifiable diffuse large B cell lymphoma

Yusuke Kanemasa, Daichi Sadato, Maya Isogai, Mina Ogawa, Chizuko Hirama, Hideya Kawaji, Tatsuro Yamaguchi, Yuka Harada, Tsunekazu Hishima, Keisuke Oboki, Tatsu Shimoyama

International Journal of Hematology · 2025-11 · 122 (5) · 631-636

DOI: 10.1007/s12185-025-04065-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Hematology, online erschienen am 12.09.2025. Verfasst von Yusuke Kanemasa und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo, 11…. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Biomarkers, Tumor. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 11 Literaturangaben. Gefördert von: the Japan Society for the Promotion of Science (JSPS) KAKENHI.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Diffuse large B cell lymphoma (DLBCL), the most common subtype of non-Hodgkin lymphoma, has variable treatment responses and distinct molecular subtypes. Despite therapeutic advances, a significant number of patients experience treatment failure or relapse. Recent genetic subtyping methods, such as the LymphGen algorithm, classify DLBCL into molecular subtypes. However, a subset of cases remains categorized as "LymphGen-unclassifiable" ("Other" group in the LymphGen classification). These cases lack distinctive genetic features and present challenges for risk assessment. In this study, we aimed to identify prognostic genetic markers specific to LymphGen-unclassifiable DLBCL. Using a discovery cohort from the National Cancer Institute, we identified genetic alterations in CDKN2A and PIM1 that were significantly associated with overall survival in this patient group. We then validated the model in a separate cohort from Komagome Hospital in Tokyo. Our model, combined with the International Prognostic Index (IPI), identified high-risk LymphGen-unclassifiable DLBCL patients within the high-risk IPI group, showing a 2-year overall survival rate of 38% versus 72%. This approach could support the development of more targeted therapies by improving prognostic accuracy and advancing understanding of LymphGen-unclassifiable DLBCL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Large B-Cell, DiffuseBiomarkers, TumorHumansPrognosisMaleFemaleMiddle AgedAgedGenetic MarkersProto-Oncogene Proteins c-pim-1Cyclin-Dependent Kinase Inhibitor p16AdultAged, 80 and overSurvival Rate

Stichwörter der Autor:innen

Diffuse large B cell lymphomaGenetic subtypeGenomic alterationsMolecular classificationPrognostic scoring model

Substanzen

Biomarkers, TumorGenetic MarkersProto-Oncogene Proteins c-pim-1Cyclin-Dependent Kinase Inhibitor p16CDKN2A protein, human

Autor:innen und Institutionen

  • Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo, 113-8677, Japan. yuusuke_kanemasa@tmhp.jp.
  • Department of Clinical Genetics, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan. yuusuke_kanemasa@tmhp.jp.
  • Research Center for Genome and Medical Sciences, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan. yuusuke_kanemasa@tmhp.jp.
  • Research Center for Genome and Medical Sciences, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.
  • Clinical Research Support Center, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan.
  • Department of Clinical Genetics, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan.

Förderung

  • the Japan Society for the Promotion of Science (JSPS) KAKENHI

Zitieren

APA

Kanemasa, Y., Sadato, D., Isogai, M., Ogawa, M., Hirama, C., Kawaji, H., Yamaguchi, T., Harada, Y., Hishima, T., Oboki, K., & Shimoyama, T. (2025). Genetic prognostic markers in LymphGen-unclassifiable diffuse large B cell lymphoma. International Journal of Hematology, 122(5), 631-636. https://doi.org/10.1007/s12185-025-04065-2

Vancouver

Kanemasa Y, Sadato D, Isogai M, Ogawa M, Hirama C, Kawaji H, et al. Genetic prognostic markers in LymphGen-unclassifiable diffuse large B cell lymphoma. International Journal of Hematology. 2025;122(5):631-636. doi:10.1007/s12185-025-04065-2

BibTeX
@article{Kanemasa2025,
  author = {Kanemasa, Yusuke and Sadato, Daichi and Isogai, Maya and Ogawa, Mina and Hirama, Chizuko and Kawaji, Hideya and Yamaguchi, Tatsuro and Harada, Yuka and Hishima, Tsunekazu and Oboki, Keisuke and Shimoyama, Tatsu},
  title = {Genetic prognostic markers in LymphGen-unclassifiable diffuse large B cell lymphoma},
  journal = {International Journal of Hematology},
  year = {2025},
  volume = {122},
  number = {5},
  pages = {631--636},
  doi = {10.1007/s12185-025-04065-2}
}
Kostenlos starten →